Growing number of patients suffering from several eye-related disorders is anticipated to propel the demand for ophthalmic therapeutics/drugs. Such advanced products are safe and effective in treating different forms of eye disorders such as dry eye, glaucoma, retinal disorders, infection or inflammation, uveitis, allergies, etc.
New Eye Drop to Reduce Intraocular Pressure
Different types of ophthalmic therapeutics/drugs are anti-inflammatory, anti-infective, anti-Vascular Endothelial Growth Factor (anti-VEGF), anti-infective, and anti-glaucoma agents. The anti-infective drugs segment led the industry in 2016 on account of the factors such as rising cases of allergic conjunctivitis. In the coming years, anti-glaucoma agents segment is expected to be the fastest-growing segment. These agents can be bifurcated further into systemic and topical drops. Some of the drugs that can be used to treat glaucoma are brimonidine, timolol, epinephrine, metipranolol, dipivefrin, pilocarpine, latanoprost, bimatoprost, and carbachol.
The growth of this segment is attributed to the continuous advent of novel therepies with innovative mechanism of action (MOA). For instance, Aerie Pharmaceuticals recently introduced Rhopressa, its first product to cure open-angle glaucoma. The product reduces elevated Intraocular Pressure (IOP) in patients suffering from ocular hypertension or open-angle glaucoma. Another product from this company named Roclatan is expected to be under trails. When approved, it is predicted to be first-known glaucoma product to reduce IOP.
Market Insights
The ophthalmic therapeutics/drug market is likely to reach USD 35.7 billion by 2025, according to a report by Grand View Research, Inc. The market is also anticipated to witness a healthy CAGR of 5.1 % during the forecast period (from 2018 to 2025). Increasing number of private and public firms investing in R&D activities to develop more effective drugs is projected to stimulate the market growth in the coming years.
Growing cases of eye-related issues owing to increasing number of geriatric population is also expected to fuel market growth in the next few years. In addition, increasing adoption of safe and effective agents to cure various ophthalmic disease can also foster market expansion. Some of the leading companies offering safe and effective ophthalmic therapeutics/drugs are Pfizer Inc.; Novartis AG; Santen Pharmaceutical Co., Ltd.; Allergan; and Merck & Co., Inc.
In-Depth Research Report On Automotive Ophthalmic Therapeutics/Drug Market:
No comments:
Post a Comment